linjc16/ctgov huggingface dataset:
Risk Factor for Readmission and Death of Lower Respiratory Infections in Older Adults

Study Overview
=================
Brief Summary
-----------------
Lower respiratory tract infection(LRTI) is a prevalent disease that threatens the health of older people worldwide. Anemia is also a common disorder in the elderly, and its prevalence increases significantly with age. Most factors that contribute to the development of anemia are improvable. Therefore, we investigated whether anemia was a risk factor for LRTI-caused readmission and death in the elderly occurring within 1 year of discharge from the hospital.

Detailed Description
-----------------
Objectives: To investigate the effect of anemia on readmission and deaths in the older adults following lower respiratory tract infection (LRTI)-caused hospitalization. Design: A retrospective cohort study. Setting and Participants: Older patients (age: ≥ 80 years) hospitalized at the Department of Geriatrics, from March 2016 to December 2019 to undergo treatment for LRTIs were included. Methods: The patients were divided into two groups (anemia and non-anemia) based on the level of hemoglobin. They were kept under observation till the occurrence of mortality event or 1 year after discharge. The primary follow-up outcome was LRTI-caused readmission and/or death.

Official Title
-----------------
Anemia is a Risk Factor for Readmission and Death of Lower Respiratory Infections in Older Adults

Conditions
-----------------
Lower Respiratory Infection, Anemia, Readmission, Death

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 80 years lower respiratory tract infection Exclusion Criteria: Died at the time of first admission Active malignancy Tuberculosis Anemia caused by gastrointestinal bleeding of unknown origin Achalasia of the cardia Could not be followed up after discharge Data were missing

Ages Eligible for Study
-----------------
Minimum Age: 80 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| anemia<br>patients with anemia | Other: no intervention<br>* no intervention<br>|
| non-anemia<br>patients without anemia | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients with Readmission and/ or Death Caused by Lower Respiratory Tract Infection(LRTI) within One Year of Discharge | Number of Patients with Readmission Caused by LRTI within One Year of Discharge. Number of Patients with Death Caused by LRTI within One Year of Discharge. | March 2016 to 27 December 2019 |
Memory and Picture Viewing Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to obtain a database of brain function from a sample of non-smokers while they do tasks in an MRI (magnetic resonance imaging) machine. Our hypothesis is that among nonsmokers, reactivity to smoking cues will be highly similar to control cues but may vary as a function of attitudes toward smoking and/or family history of smoking. We also hypothesize that brain activity during the n-back task will be more similar to data collected during this task when smokers are not abstinent.

Detailed Description
-----------------
Thirty six non-smokers will undergo functional magnetic resonance imaging (fMRI) scanning. During scanning participants will complete the n-back task-a measure of working memory-and the cue-reactivity task-a measure of responses to smoking cues. Before scanning, participants will complete a training session where they will be familiarized with the tasks. All participants will have to pass a screening visit in order to be included in the study.

Official Title
-----------------
Memory and Picture Viewing Study

Conditions
-----------------
Healthy, Brain Reactivity of Non-smokers Undergoing fMRI Scanning

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: generally healthy right-handed non-smokers between the ages of 18-55 an expired CO concentration of 5 ppm or less; or a negative urine cotinine test of 100 ng/mL or less (to confirm a non-smoker) having smoked < 50 cigarettes in their lifetime Exclusion Criteria: inability to attend all sessions significant health problems (hypertension, emphysema, seizure disorder, history of significant heart problems) use of psychoactive medications use of any tobacco or nicotine containing products current alcohol or drug abuse use of illegal drugs as measure by a urine drug screen presence of conditions that would make MRI unsafe (pacemaker, metallic implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>non-smokers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brain reactivity |  | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fMRI, non-smokers
A Pharmacokinetics Study of Intravenous Ascorbic Acid

Study Overview
=================
Brief Summary
-----------------
This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Detailed Description
-----------------
The objectives of this study are: To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV). To evaluate the safety and tolerability of AA administered intravenously.

Official Title
-----------------
A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers

Conditions
-----------------
Pharmacokinetics

Intervention / Treatment
-----------------
* Drug: Ascor L 500® (Ascorbic Acid Injection, USP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is between the ages of 18 and 45 years, inclusive. Has a body mass index (BMI) between 18 and 32 kg/m2. Of sound health and has the ability to understand the requirements of the study and is willing to comply with all study requirements and procedures. Exclusion Criteria: Participates in activities that would not allow accurate evaluation of the pharmacokinetics of Ascorbic Acid Medical or physical conditions that would not allow safe participation and/or accurate evaluation of the pharmacokinetics of Ascorbic Acid Has participated in an investigational drug study within the 30 days prior to CRU admission.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Group<br> | Drug: Ascor L 500® (Ascorbic Acid Injection, USP)<br>* A sterile, solution containing 500 mg ascorbic acid per mL<br>* Other names: Ascorbic Acid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of Ascorbic Acid (µM) in plasma |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system |  | 1 day | 
| Changes from Baseline in clinical laboratory and vital signs to discharge |  | 1 day | 
| Changes from pre-dose physical exam findings to discharge |  | 1 day |
Study of the Effect of a Calcium-rich Diet on Bone Health in Girls

Study Overview
=================
Brief Summary
-----------------
The aim of this experimental study was to test the effect of increasing dietary calcium intake to 1500 mg/day on increases in bone quality in adolescent females. The hypothesis to be tested is: adolescent females who consume a high calcium diet will have a greater increase in bone quality, as measured by densitometry and ultrasound, than adolescent females who consume their usual dietary calcium intake.

Official Title
-----------------
Effect of Calcium Foods on Bone Quality in Pubertal Females

Conditions
-----------------
Bone Health

Intervention / Treatment
-----------------
* Other: calcium-rich diet
* Other: Calcium rich diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Inclusion criteria were being female and nine years of age with usual dietary calcium intake 1100 mg/day or less. Exclusion Criteria: Exclusion criteria included history of any of the following: lactose intolerance, milk allergy, corticosteroid or anticonvulsant therapy, familial hypercholesterolemia, mental or physical handicaps, cancer, rheumatoid arthritis, asthma, or any significant health problem reported by the parents. We also excluded any child who had a body mass index (BMI)85th percentile for age and gender and children who practiced or played any organized sport (including gymnastics or dance) more than three times per week.

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: calcium group<br>dietary calcium intake of 1500 mg/d | Other: calcium-rich diet<br>* dietary calcium intake of 1500 mg/d<br>|
| Experimental: calcium-rich diet (1500 mg/d)<br>calcium intake from food | Other: Calcium rich diet<br>* dietary intake of 1500 mg/d from food<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The specific aim of this project was to test the effect of increasing dietary calcium intake to 1500 mg/day on increases in bone quality in pubertal females beginning at age nine. |  | 9 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bone health, bone density, bone mass
The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian Population

Study Overview
=================
Brief Summary
-----------------
Abdominal aortic aneurysm(AAA) occurs when the infrarenal aorta expands to a maximal diameter of 3.0cm or greater. Although AAA may asymptomatic for many years, almost one third eventually rupture if left untreated. Several randomized trials showed that ultrasonographic screening for AAA could reduce the frequency of acute operations and AAA-related mortality. However, all of randomized trials were performed in Western countries. There was no randomized trials for AAA screening in Asian countries. This randomized, controlled trial is to analyze the benefits of screening old population for AAA in Korea.

Detailed Description
-----------------
Old population, aged from 60 to 85 years, are randomized into two groups; one group is invited for ultrasonographic screening for AAA, and the other acts as age- and sex-matched controls. For screening group, The anterioposterior and transverse diameter of the infrarenal aorta is measured at their maximal sizes. The subsequent surveillance of screened patients is done as follows Aortic diameter less than 3.0cm, no further testing AAA 3 to 4cm, ultrasonographic follow-up every year AAA 4 to 5cm, ultrasonographic follow-up every 6 months AAA greater than 5cm, referral to a vascular surgeon For control group, the information for any causes of death is collected every year.

Official Title
-----------------
The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian: A Randomized, Controlled Trial

Conditions
-----------------
Aortic Aneurysm, Abdominal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all men aged 60 to 85 years women aged 60 to 85 years with cardiovascular risk factors such as hypertension, hyperlipidemia, peripheral arterial occlusive disease, coronary artery disease, cerebrovascular attack. men and women older than 50 years with a family history of AAA Exclusion Criteria: people who was diagnosed with AAA people who underwent aneurysm repair such as open aneurysm repair or endovascular aneurysm repair People who underwent abdominal aortic surgery such as aortobifemoral bypass People whose life expectancy is less than 2 years People who appear unfit for repair of AAA people who do not agree with this study

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aortic aneurysm, abdominal, Screening, Mortality
Prospective Comparison of Immunological Benefit of Laparoscopic Colectomy

Study Overview
=================
Brief Summary
-----------------
This study aimed to clarify existence of immunological benefit of laparoscopic colon cancer surgery compared to open colon surgery.

Detailed Description
-----------------
Patients with clinical stage Ⅲ left colon and upper rectal cancer were prospectively assigned to undergo LC (n=35) or OC (n=39). Factors related to cellular immunity of host (total lymphocyte count, CD4 lymphocyte, CD8 lymphocyte, CD4/CD8 ratio, HLA-DR expression on monocyte (mHLA-DR)) were examined preoperatively, on the 1st day of operation (POD1) and the 5th day of operation (POD5).

Official Title
-----------------
Prospective Comparative Study of Immunological Benefit Between Laparoscopic Colectomy and Open Colectomy

Conditions
-----------------
Immunity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy proven of colon cancer Preoperatively suspected as clinical stage III colon cancer Lesion located Descending colon, sigmoid colon and upper rectal cancer Exclusion Criteria: Could not perform curative resection Intestinal obstruction, perforation, intra-abdominal abscess Severe medical illness Immunopathy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OC<br>Open colorectal resection | |
| LC<br>Laparoscopic colorectal resection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune factors |  | post OP 5th day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative complications |  | POD 7th days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colon cancer, laparoscopic colorectal surgery, cellular immunity, HLA-DR expression on monocyte
Predicting Factors for Asthma Remission in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the predicting factors for asthma remission in children.

Detailed Description
-----------------
Children who were diagnosed as having asthma during the period of 2004-2007 and reevaluated in 2015.

Official Title
-----------------
Predicting Factors for Asthma Remission in Children

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: Clinical asthma remission


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children who were diagnosed as having asthma during the period of 2004-2007. Exclusion Criteria: Patients who had underlying disease with chronic respiratory disease (ex. tuberculosis, bronchiectasis), primary immunodeficiency, other seriously interfering diseases Medical records have been lost.

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Clinical asthma remission<br>Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months. | Other: Clinical asthma remission<br>* Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of factors associated with asthma remission |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma remission rate |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma remission, Predicting factors, Children
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Cytomegalovirus (CMV) infects most of the world population. This study is to understand if chemotherapy will increase the chance of reactivating CMV. The results may help us in determining when treatment is needed and perhaps Why is it needed.

Detailed Description
-----------------
Despite CMV reactivation has been clearly described in patients underwent transplantation, this phenomenon has not been studied in patients undergoing chemotherapy. Our purpose is to understand if CMV number increases in monocytic leukocytes during chemotherapy and how is the host response to that changes. Virus load will be studied by quantitative PCR, host response will be studied by measuring patient's anti-CMV IgG, CMV-associated symptoms, serum IFN-r and TNF-a.

Conditions
-----------------
Cancer, Cytomegalovirus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of any cancer chemotherapy is needed for more than 6 months age>20 years old Exclusion Criteria: those who do not agree to participate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer under chemotherapy
Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD

Study Overview
=================
Brief Summary
-----------------
THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing. This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.

Conditions
-----------------
Electrophysiology

Intervention / Treatment
-----------------
* Procedure: Electroretinography (ERG), Visual Evoked Potentials (VEP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of CNV secondary to AMD No other ocular disease No history of kerato-refractive surgery No epilepsy Ability to perform electrophysiologic study Exclusion Criteria: Pregnancy Minority Epilepsy History of kerato-refractive surgery

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Electroretinography (ERG), Visual Evoked Potentials (VEP)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate and compare the effects of treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus on stable Highly Active Antiretroviral Therapy including a Protease Inhibitor after the period of 48 weeks.

Conditions
-----------------
Insulin Resistance

Intervention / Treatment
-----------------
* Drug: metformin, rosiglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: documented HIV infection stable Protease Inhibitor containing HAART regimen for at least 12 months impaired glucose tolerance elevated insulin levels (above 20 mIU/l) Exclusion Criteria: patients already taking oral hypoglycaemic treatment or insulin heart failure NYHA I-IV liver disease or kidney disease elevated AST or ALT above 2 times upper normal range elevated creatinine (above 150 mmol/l)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: metformin, rosiglitazone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting plasma glucose, basal insulin levels |  | 48 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin resistance, beta cell function |  | 48 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
insulin, rosiglitazone, metformin, hiv, protease inhibitors